Organovo Holdings (ONVO), an early commercial stage company, designs and creates functional and three-dimensional (3D) human tissues for use in medical research and therapeutic applications.
ONVO develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. Its 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
ONVO offers two commercial products, which include ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing a suite of standardized and 3D human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology, or disease for use in drug discovery and development, and disease modeling; and 3D human tissues for clinical applications, such as therapeutic liver tissue patch.
Organovo Holdings, Inc. was founded in 2007 and is headquartered in San Diego, California.
November 6, 2019
RegMed Investors’ (RMi) closing bell: Framing the main takeaway … pricing, volume and volatility!
November 6, 2019
RegMed Investors’ (RMi) pre-open: bada-bing, they – the sector ain’t do'in our thing
October 31, 2019
RegMed Investors’ (RMi) closing bell: The sector risks are still to the downside
October 31, 2019
RegMed Investors’ (RMi) pre-open: a happy haunting session on the last session of a roguery month
October 30, 2019
RegMed Investors’ (RMi) closing bell: strength came from trading the downside
October 26, 2019
RegMed Investors’ (RMi) closing bell: the oversold are flirting with the upside and it ain’t a love match
October 24, 2019
RegMed Investors’ (RMi) closing bell: Low volume and percentage moves do not glamorize the sector for short-term investment
35 companies, 1 interpreter!
Insight, foresight and recommendation
Organovo Holdings (ONVO) – ONVO opened on 1/2/18 at $1.39, floating to $1.45 by 2/1 and slipping to $1.05 by 2/12. A show me stock ... the FDA recently granting orphan designation for our NovoTissues® treatment of Alpha-1 antitrypsin deficiency (“A1AT”), our path to commercializing this therapeutic comes with significant developmental and economic incentives. With few alternative therapies and a high annual cost of care, patient need is great in treating this rare, debilitating liver disease. ONVO has also begun new studies in a second therapeutic indication within the category of inborn errors of metabolism, Fumarylacetoacetate Hydrolase (“FAH”) deficiency, and look forward to reporting proof-of-principle data in Q2-3/18. A show me stock ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors